🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
IBI306 is a fully human monoclonal antibody that binds proprotein convertas...
Status
Completed
Location
Peking University First Hospital
Start Date
2019-03-07
Trial ID
NCT03815812
A study to evaluate safety and efficacy of IBI306 in subjects with homozygo...
Status
Completed
Location
Beijing Anzhen Hospital, Capital Medical University
Start Date
2019-09-29
Trial ID
NCT04031742
This is a multicenter, prospective, open-label, Phase II, four-arm parallel...
Status
Recruiting
Location
Sun Yat-sen Memorial Hospital
Start Date
2026-07-01
Trial ID
NCT07717242
IBI306 is a bio-innovative drug against proprotein convertase subtilisin 9 ...
Status
Unknown
Location
xili People's Hospital
Start Date
2019-11-05
Trial ID
NCT04948008
Treatments Being Tested
IBI306 is a fully human monoclonal antibody that binds proprotein convertas...
Status
Completed
Location
Peking University First Hospital
Start Date
2017-11-27
Trial ID
NCT03366688
This trial is conducted in China. The purpose of this study is to evaluate ...
Status
Completed
Location
Aerospace Center Hospital
Start Date
2023-03-06
Trial ID
NCT05792917
Treatments Being Tested
This study plans to enroll several patients with heterozygous familial hype...
Status
Unknown
Location
xili People's Hospital
Start Date
2020-09-10
Trial ID
NCT04759534
Treatments Being Tested
IBI306 is a fully human monoclonal antibody that binds proprotein convertas...
Status
Completed
Location
Peking University First Hospital
Start Date
2020-04-29
Trial ID
NCT04289285
Treatments Being Tested
This study is designed for multi-center, double-blind, randomized, placebo-...
Status
Completed
Location
Peking University First Hospital
Start Date
2021-02-09
Trial ID
NCT04709536
This is a multi-center, randomized, double-blind, placebo-controlled phase ...
Status
Active Not Recruiting
Location
Peking University Third Hospital
Start Date
2026-04-01
Trial ID
NCT07473960